Adult Clinical Trials

For more information about participating in a clinical trial please contact either Eileen Mederos, RN, Clinical Research Nurse at emede1@lsuhsc.edu

*Trials are current as of March 5, 2012.
 

Brain Cancer Trials 

ECOG 3F05: Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas

RTOG 0539: A Phase II Trial of Observation For Low-Risk Meningiomas and of Radiotherapy for Intermediate and High-Risk Meningiomas

RTOG 0929: A Randomized Phase I/II Study Of Abt-888 In Combination With Temozolomide In Recurrent (Temozolomide Resistant) Glioblastoma
 

Breast Cancer Trials

IRB #6389: NSABP B-39/RTOG 0413: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer

CALGB 70604: A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer

ECOG E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

NCCTG MA32: A Phase III Randomized Trial Of Metformin Versus Placebo On Recurrence And Survival In Early Stage Breast Cancer

NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

SCUSF 0806: A Phase II placebo-controlled trial of lisinopril and CoregCR® to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin®)

Gastrointestinal Trials (GI)

CALGB 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

IRB # 7647C: CALGB 80802: Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

CALGB 90802: Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab For Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors

ECOG 2208: A Phase II Randomized Study of Paclitaxel With Versus Without Cixutumumab as Second-Line Therapy in Patients With Metastatic Esophageal or Gastroesophageal Junction Cancer

E3205: Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and Radiation in Immunocompetent Patients with Anal Carcinoma

ECOG E7208: A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab, in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

NCCTG N08CB: A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity

NSABP PROTOCOL P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer

SWOG 0518: Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) In Advanced Poor Prognosis Carcinoid Patients

SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III

Genitourinary Trials (GU)

IRB #6951C: R0534: A Phase III Trial Trial of Short-term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed-Only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy

IRB #7111C: CALGB 90203: Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

IRB #7214C: CALGB 90202: A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone

IRB #7627 CCCWFU 98110: A Randomized Phase II Dose Finding Study of ArginMax for Its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated with Radiotherapy

CALGB 70807: The Men’s Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance

CALGB 90601: A Randomized Double Blind Phase III Study comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma

ECOG 3805: CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

RTOG 0526: A Prospective Phase II Trial Of Transperineal Ultrasound-Guided Brachytherapy For Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy

RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Ratiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: a Phase III Randomized Trial

Gynecology

GOG 0249: A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High-Risk, Early Stage Endometrial Cancer

Head and Neck Cancer Trials

IRB #7079C: E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer 

RTOG 0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery

RTOG 0912: A Randomized Phase II Study Of Concurrent Intensity Modulated Radiation Therapy (Imrt), Paclitaxel And Pazopanib (Nsc 737754)/Placebo, For The Treatment Of Anaplastic Thyroid Cancer

RTOG 0920:  A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer

RTOG 1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
 

Lung Trials

IRB #6937C: E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (>4 cm) – IIIA Non-Small Cell Lung Cancer

IRB #7297C: S0819, "A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)"

CALGB 30607: Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib, as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

CALGB 30801: A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer

ECOG 5508: Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

RTOG 0813: Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients

Lymphoma Trials

CALGB 50604: Phase III Trial of Response- Adapted Chemotherapy Based on Positron Emission Tomography for Non-bulky Stage I and II Hodgkin Lymphoma 

SWOG 0816: A Phase II Trial of Response Adapted Therapy of Stage III-IV Hodgkin’s Lymphoma Using Early Interim FDG-PET Imaging